The Tisch Cancer Institute has an outstanding team of scientists and physicians with collective experience across all cancers, who along with our administrative and shared resource specialists, provide the infrastructure for innovative translational research. Thanks to the expertise of this team and our National Cancer Institute (NCI) Cancer Center Support Grant, which provides important funding and confers NCI-Designated Cancer Center status, we are well positioned to pursue our mission of advancing basic, clinical, and population health cancer research in order to prevent cancer in healthy individuals and improve the lives of people with cancer and their families in our diverse communities.

With a collegial and nimble approach that allows us to quickly respond to new discoveries and challenges, we are deciphering the mechanisms that enable cancer to resist treatment and pioneering new modalities to combat it. We are committed to developing effective therapy options through a robust portfolio of clinical trials, while promoting equity in cancer care and addressing the unique needs of our diverse patient populations.

Our clinical and translational research platform includes grant-funded projects addressing a full array of cancer types, with particular emphasis on cancers that are prevalent in our catchment area across New York City—breast, colorectal, liver, lung, and prostate cancers, and multiple myeloma.

We continually welcome new investigators from diverse backgrounds to our faculty. With proven expertise and promising potential, they are exploring the complexities of cancer behavior as they pursue novel strategies to advance the course of treatment and survival.

Our standards for collaboration and excellence are second to none. I invite you to peruse our website and learn more about the great strides we are making in cancer research and improved care and outcomes for patients.

Ramon Parsons, MD, PhD
Director, The Tisch Cancer Institute